Depression Depressive Disorders
Conditions
Interventions
In all arms, patients will receive 10,000 lux BLT in the morning for 30 min/day
on 5 consecutive days. Treatment duration will be one, two or three weeks,
depending on the remittance of depressive s
Sponsors
Universiteit Leiden
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Age between 18 and 65. - Diagnosis of unipolar or bipolar depression (seasonal or non-seasonal) - A current depressive episode - Sufficient knowledge of Dutch or English language to fill in questionnaires
Exclusion criteria
Exclusion criteria: - A current (hypo)manic or mixed episode - Current psychotic episode - Prominent active suicidality - Antidepressant therapy that started less than 2 months prior to study entry - Participants with bipolar disorder that are not on mood stabilizing medication in a recommended dose for the last month prior to study entry - Use of melatonin or agomelatine in the last month - Current use of antibiotics - Current use of light sensitivity-increasing medication - Travelled more than 1 time zone or to a sunny holiday destination/wintersports during the past month - Pre-existing eye and skin disorders (retinitis pigmentosa, porphyria, chronic actinic dermatitis and sun-induced urticaria) - Systemic disorders with potential retinal involvement (rheumatoid arthritis and systemic lupus erythematosus) - Suffering from (retinal) blindness, severe cataract, glaucoma or colour blindness - Participated in night shift work in the last three months - Light-induced migraine and epilepsy - Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is clinical improvement, as indexed by a difference in MADRS scores between the baseline and 4 weeks after the start of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary clinical outcome measures are: time to recovery (the number of treatment weeks needed to achieve remission), remission rate (percentage of patients that score lower than 6 on the MADRS 4 weeks after the start of the treatment); and response rate (percentage of patients with at least 50% reduction in MADRS -score). | — |
Countries
Netherlands
Outcome results
None listed